Sustaining the mindset of innovation
The importance of the pharma industry during the covid-19 pandemic can’t be overstated.
But what is often forgotten is the transformation that the sector had to go through to be able to respond to one of the greatest challenges of our generation. The way traditional pharma companies worked with biotechnology firms and public bodies to share information, conduct trials and collaborate to develop and distribute the covid-19 vaccines serves as evidence of how a collaborative and agile mindset can help drive results that are good for business and society at large.
The question for pharma leaders is how to keep the momentum. How can innovation be sustained through culture and a new mindset? How can cross-industry collaboration become the norm, rather than exception?
How we help our Pharma Clients
Every business is different. Every business feels the impact of change differently.
At Headspring, we help organisations leverage the power of their people to create a positive economic, social, and environmental impact. We partner with our clients to co-create transformative learning experiences that empower their leaders to make responsible decisions, and achieve better outcomes for all stakeholders.
Customisation is our core expertise. Our approach is adaptable, but one thing is always the same: we start with your real business needs. If you have a complex structure with multiple learning needs, this might be right for you.Discover Our Approach →
We worked with our clients to develop a range of pre-designed solutions aimed at solving some of the most complex business challenges. If you already know your learning needs, these might be right for you.Discover Pre-Designed Solutions →
What’s Next for the Pharma Industry and How Leaders Can Sustain Innovation
The pharmaceutical sector has been under the global spotlight like never before, and further challenges lie ahead. With vaccination programs beginning to level off the COVID-19 pandemic, pharmaceutical companies may once again find themselves in the eye of the storm, as unlocking delayed treatments and paused clinical trials causes healthcare organisations to experience a sudden surge in demand.
Who have we helped?
These are some of the pharmaceutical organisations that we have helped with programmes designed to bring out the best in their people.
One future. Multiple paths
A closer look at the issues making waves in the sector. Insights from the FT into topics from innovation and tech transformation to the businesses helping to build a sustainable future.
From price-gouging to its role in the opioids scandal, Big Pharma has long been the target of criticism from politicians, especially in the US. But a brief rapprochement following the rapid development of coronavirus vaccines has soured over the issue of intellectual property.Read on the FT →
Leadership lessons from the AstraZeneca chief, as he deals with challenges of developing a Covid-19 jab that could save millionsRead on the FT →
Can AI take healthcare where doctors don’t want to go? What does it mean for AI to augment human perception? In this episode the FT’s Madhumita Murgia takes us to a small village in rural India where AI is being used to help doctors better diagnose tuberculosis.Listen on the FT →
The Financial Times explores the influence that the sector has over the United States' trade policy and how this influence is changing under the new administration.Read on the FT →
Partnerships with local start-ups hit record despite data security and IP protection concernsRead on the FT →
The biotech group’s founders have ambitions to build, rather than sellRead on the FT →